Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of clesacostat in healthy Japanese adults
NCT03597217Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of clesacostat in Nonalcoholic steatohepatitis (NASH) (3 cohorts), sponsored by Pfizer. Primary endpoints: Area under the plasma concentration time profile from time zero to the time of the last quantifiable concentration, Maximum observed plasma concentration and 6 more. Started Aug 2018; status: completed.
02
Drugs
clesacostat
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03597217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03597217.